lifestyle spending accounts glp-1 prescriptions weight management reimbursement How Pharmacy Plans Are Managing Coverage in 2025 GLP-1 Antagonists Increase Plan Drug

A novel mouse model of glucagon-like peptide-1 receptor expression: a look at the brain

GLP-1 medications slow the movement of food through the digestive tract, which can affect the balance of bacteria in the gut microbiome over time

Building Patient Trust and Continual Care Patients want details about what theyre getting, why youre prescribing it, how youll monitor them, and what happens if anything changes

Amgen (NASDAQ:AMGN) has reported favorable findings at 52 weeks from a double-blind, dose-ranging Phase 2 trial involving MariTide ( maridebart cafraglutide , previously known as AMG 133), which is a novel antibody-peptide conjugate given subcutaneously on a monthly basis or less

Patients with high GAD65 antibody titers are more likely to develop insulin dependency

Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs